You just read:

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

News provided by

Regeneron Pharmaceuticals, Inc.

Jul 08, 2015, 10:00 ET